United States: Capitol Hill Healthcare Update May 9, 2017

House approval last week of legislation repealing and replacing most of the Affordable Care Act (ACA) sets up a showdown in the Senate, where GOP leaders will confront a familiar web of political, policy and procedural obstacles that took House Republicans five months to navigate.

Majority Leader Mitch McConnell and key committee chairmen must reconcile differences between conservatives who say the House bill didn't go far enough to end the ACA and moderates who want additional protections on pre-existing conditions and concessions to states that expanded Medicaid. Other senators also are demanding changes to the House bill's provision ending federal funding for Planned Parenthood.

The coming weeks will feature both behind-the-scenes negotiating and public declarations as the competing factions jockey to shape the Senate legislation. Given the policy differences and procedural hurdles, a vote before Memorial Day isn't likely. Instead, senators are sketching out a time line for a potential vote in June – but even that could slip to later in the summer.

GOP leaders are hamstrung by the policy changes they can make to the underlying legislation. The House-approved American Health Care Act (AHCA) is a budget reconciliation bill, which needs only 51 Senate votes to pass, not the usual 60 votes to approve legislation. But only certain provisions are eligible to be included in a reconciliation bill – for example, ending the ACA's individual mandate isn't eligible, but repealing the tax on individuals who don't buy insurance is.

The Congressional Budget Office later this month will release its economic analysis of the House-approved bill. The Senate parliamentarian, Elizabeth MacDonough will also require a CBO score of any fresh Senate language to determine whether it's eligible to be included in the reconciliation bill. MacDonough's procedural rulings will be effectively binding because Republicans lack the votes to override them.

Republicans have 52 senators – Vice President Pence could vote to break any 50-50 tie – leaving GOP leaders with a narrow pathway to resolve competing intra-party political and policy demands while navigating the Senate's complex rules.

McConnell convened a group of senators – conservatives, moderates and committee chairmen – to try to forge consensus on next steps. The Senate bill won't be developed by committees with jurisdiction over healthcare policy. Instead, Republicans will bring their modifications directly to the Senate floor as an amendment to the House bill. Any changes to the House bill would require a new House vote before final legislation could be sent to the White House.

The Senate largely sat on the sidelines while the House took months to develop an ACA repeal bill it could pass. To avoid the pitfalls that bedeviled House leaders, Senate Finance Committee Chairman Orrin Hatch said last week that the Senate "must manage expectations and remain focused on the art of the doable."

Senate to Vote on Gottlieb This Week

Senate Majority Leader Mitch McConnell scheduled a preliminary vote Monday on President Trump's nominee to head the FDA, paving the way for a final Senate vote later this week. Dr. Scott Gottlieb is expected to win Senate confirmation although most Democrats on the Senate HELP Committee opposed his nomination last month, saying he was too close to the pharmaceutical industry he would be in charge of overseeing. During President George W. Bush's administration, Gottlieb served as deputy FDA commissioner and also worked at CMS. He is a cancer survivor, having previously been diagnosed with Hodgkin's lymphoma.

Senate Panel to Vote on User Fee Bill

The Senate HELP Committee on Wednesday is expected to vote on legislation reauthorizing FDA user fees for brand and generic drugs, biosimilars and medical technology. The committee is also expected today to release a manager's amendment of narrow bipartisan provisions that would be included in the user fee bill, like changes to medical inspections, diagnostics, accessories, post-market pilots and contrast agents used in imaging. Other changes could include legislation introduced last week that expanded eligibility to participate in clinical trials in an effort bridge differences between patient groups lobbying for right-to-try legislation and drug companies opposed to easier access to unapproved medicines.

It's possible Sens. Bernie Sanders (I-Vt.) or Elizabeth Warren (D-Mass.) could force votes on amendments related to drug pricing or Bayh-Dole march-in rights. But committee leaders are working to ensure only amendments pre-vetted and with bipartisan support are added to the package.

The House Energy and Commerce Committee last week held a hearing on potential amendments to the user fee agreements, but that committee's schedule for voting on the broader user fee bill isn't clear. Current user fees expire Sept. 30, and Congress is expected to approve new user fees by this summer.

House Bill Would Allow Suits Against Device Makers

Legislation introduced last week in the House would nullify a 2008 Supreme Court decision and allow state lawsuits against medical technology manufacturers. The court's 8-1 ruling held that federal law prohibits claims challenging safety or effectiveness of Class III medical devices that undergo the FDA's most stringent review and approval process. Introduced by Rep. Rosa DeLauro (D-Conn.), the bill has been introduced in each congressional session since the Supreme Court's ruling. Although supported by liberal Democrats and pushed externally by trial lawyers, the bill has failed to gain traction in Congress.

Only about 2 percent of all medical devices are approved under FDA's premarket approval pathway referenced in the court ruling. Patients can still sue if a medical device is manufactured improperly or if a company misleads the FDA about the device's safety or effectiveness.

Senate Committee Delays CHIP Hearing

As expected, the Senate Finance Committee delayed a hearing scheduled for this week on reauthorizing the Children's Health Insurance Program (CHIP). House passage last week of the AHCA forced the delay, as key senators on the committee will begin focusing on drafting the Senate GOP version of the health overhaul. The CHIP hearing hasn't been rescheduled. Still, Congress is likely to reauthorize the program – which enjoys wide bipartisan support – before it expires Sept. 30.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions